S&P ends higher after gyrations on reopening optimism, weak data, trade woes

FILE PHOTO: The New York Stock Exchange (NYSE) is seen in the financial district of lower Manhattan during the outbreak of the coronavirus disease (COVID-19) in New York City, U.S.

The S&P 500 closed higher after swinging between gains and losses on Friday as investors weighed worries about Sino-U.S. trade relations and weaker-than-expected U.S. economic data against growing optimism that easing coronavirus restrictions would boost activity this month.

Economic data painted a grim picture on Friday as U.S. retail sales and manufacturing output showed record declines in April due to virus-related stay-at-home orders.

The data came after U.S. President Donald Trump ratcheted up trade tensions with China by moving to block semiconductor shipments to China’s Huawei Technologies from global chipmakers.

China was swift to respond with a report saying it was ready to put U.S. companies on an “unreliable entity list,” according to the Global Times.

The combination of trade tensions and weak data had sent S&P 500 down around 1.3% earlier in the session but for much of the afternoon session it oscillated between positive and negative territory.

“We got the Friday jitters on China trade but late this afternoon the market turned its focus on reopenings,” said John Augustine, chief investment officer at Huntington National Bank in Columbus, Ohio.

“We’re smack in the middle of May and think this might be the worst of the economic numbers. There’s a chance they start to slowly turn positive,” said Augustine citing moves by most states to at least partially reopen their economies.

Unofficially, the Dow Jones Industrial Average .DJI rose 60.08 points, or 0.25%, to 23,685.42, the S&P 500 .SPX gained 11.2 points, or 0.39%, to 2,863.7 and the Nasdaq Composite .IXIC added 70.84 points, or 0.79%, to 9,014.56.

The trade worries sent the Philadelphia Semiconductor index .SOX down on the day.

“Today has very much been about this battle of conflicting factors,” said Ed Perks, multi-asset solutions’ chief investment officer at Franklin Templeton, adding that without “something that’s going to give us direction” investors are viewing it as a lackluster Friday.

The small-cap Russell 2000 outperformed and among its top percentage gainers was Sorrento Therapeutics Inc (SRNE.O) after the company’s experimental antibody candidate showed potential in blocking COVID-19 infections in early studies.

Was it worth reading? Let us know.